



Clinical trial results:

Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study

Summary

EudraCT number	2009-016870-33
Trial protocol	FR
Global end of trial date	01 March 2016

Results information

Result version number	v1 (current)
This version publication date	06 August 2025
First version publication date	06 August 2025

Trial information

Trial identification

Sponsor protocol code	CILENT-0902
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01165333
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Centre Oscar Lambret
Sponsor organisation address	3 Rue Frédéric Combemale, Lille, France, 59000
Public contact	Marie VANSEYMORTIER, Centre Oscar Lambret, 33 320295918, promotion@o-lambret.fr
Scientific contact	Pierre LEBLOND, Centre Oscar Lambret, pierre.leblond@ihope.fr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 March 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 March 2016
Global end of trial reached?	Yes
Global end of trial date	01 March 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

- To determine the Maximal Tolerated Dose (MTD) of Cilengitide, administered intravenously over 60 minutes, twice a week, in children and young adults with newly diagnosed diffuse intrinsic pontine glioma, in combination with radiation therapy

Protection of trial subjects:

This clinical trial will be conducted in accordance with the protocol, the ethical principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical Assemblies, the International Conference on Harmonization (ICH) consolidated Guideline E6 for Good Clinical Practice (CPMP/ICH/135/95), and all applicable laws and regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 September 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 32
Worldwide total number of subjects	32
EEA total number of subjects	32

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	28
Adolescents (12-17 years)	4
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 32 patients were included in the study

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

This is a phase I trial

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	level 1: 240 mg/m ² /infusion
------------------	--

Arm description: -

Arm type	dose escalation
Investigational medicinal product name	Cilengitide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Each vial contains 500 mg Cilengitide per 33.3 mL solution (i.e. 15 mg/mL of Cilengitide). Vials have to be carefully inverted 3-5 times before use to ensure a homogenous distribution of Cilengitide in the vial. Cilengitide will be given as an i.v. infusion. It will be diluted with 0.9% isotonic sodium chloride to a final volume of 250 mL in a standard polyvinyl chloride infusion bag (alternatively standard polyethylene or polyethylene/polypropylene bags can be used).

Arm title	level 2: 480 mg/m ² /infusion
------------------	--

Arm description: -

Arm type	dose escalation
Investigational medicinal product name	Cilengitide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Each vial contains 500 mg Cilengitide per 33.3 mL solution (i.e. 15 mg/mL of Cilengitide). Vials have to be carefully inverted 3-5 times before use to ensure a homogenous distribution of Cilengitide in the vial. Cilengitide will be given as an i.v. infusion. It will be diluted with 0.9% isotonic sodium chloride to a final volume of 250 mL in a standard polyvinyl chloride infusion bag (alternatively standard polyethylene or polyethylene/polypropylene bags can be used).

Arm title	level 3: 720 mg/m ² /infusion
------------------	--

Arm description: -

Arm type	dose escalation
----------	-----------------

Investigational medicinal product name	Cilengitide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Each vial contains 500 mg Cilengitide per 33.3 mL solution (i.e. 15 mg/mL of Cilengitide). Vials have to be carefully inverted 3-5 times before use to ensure a homogenous distribution of Cilengitide in the vial. Cilengitide will be given as an i.v. infusion. It will be diluted with 0.9% isotonic sodium chloride to a final volume of 250 mL in a standard polyvinyl chloride infusion bag (alternatively standard polyethylene or polyethylene/polypropylene bags can be used).

Arm title	level 4: 1200 mg/m ² /infusion
------------------	---

Arm description: -

Arm type	dose escalation
Investigational medicinal product name	Cilengitide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Each vial contains 500 mg Cilengitide per 33.3 mL solution (i.e. 15 mg/mL of Cilengitide). Vials have to be carefully inverted 3-5 times before use to ensure a homogenous distribution of Cilengitide in the vial. Cilengitide will be given as an i.v. infusion. It will be diluted with 0.9% isotonic sodium chloride to a final volume of 250 mL in a standard polyvinyl chloride infusion bag (alternatively standard polyethylene or polyethylene/polypropylene bags can be used).

Arm title	level 5: 1800 mg/m ² /infusion
------------------	---

Arm description:

3 patients in escalation phase + 15 patients in extended phase

Arm type	dose escalation
Investigational medicinal product name	Cilengitide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Each vial contains 500 mg Cilengitide per 33.3 mL solution (i.e. 15 mg/mL of Cilengitide). Vials have to be carefully inverted 3-5 times before use to ensure a homogenous distribution of Cilengitide in the vial. Cilengitide will be given as an i.v. infusion. It will be diluted with 0.9% isotonic sodium chloride to a final volume of 250 mL in a standard polyvinyl chloride infusion bag (alternatively standard polyethylene or polyethylene/polypropylene bags can be used).

Number of subjects in period 1	level 1: 240 mg/m ² /infusion	level 2: 480 mg/m ² /infusion	level 3: 720 mg/m ² /infusion
Started	3	3	3
Completed	3	3	3
Not completed	0	0	0
Adverse event, non-fatal	-	-	-

Number of subjects in period 1	level 4: 1200 mg/m ² /infusion	level 5: 1800 mg/m ² /infusion
Started	5	18

Completed	3	18
Not completed	2	0
Adverse event, non-fatal	2	-

Baseline characteristics

Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	32	32	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
median	6		
full range (min-max)	3 to 15	-	
Gender categorical			
Units: Subjects			
Female	15	15	
Male	17	17	

End points

End points reporting groups

Reporting group title	level 1: 240 mg/m ² /infusion
Reporting group description: -	
Reporting group title	level 2: 480 mg/m ² /infusion
Reporting group description: -	
Reporting group title	level 3: 720 mg/m ² /infusion
Reporting group description: -	
Reporting group title	level 4: 1200 mg/m ² /infusion
Reporting group description: -	
Reporting group title	level 5: 1800 mg/m ² /infusion
Reporting group description:	
3 patients in escalation phase + 15 patients in extended phase	

Primary: MTD (Maximal Tolerated Dose)

End point title	MTD (Maximal Tolerated Dose) ^[1]
End point description:	
End point type	Primary
End point timeframe:	
MTD during the first 6 weeks of study treatment	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a phase I dose escalation. The main endpoint aims to determine the MDT (maximal dose tolerated). No formal statistical analysis was planned

End point values	level 1: 240 mg/m ² /infusion	level 2: 480 mg/m ² /infusion	level 3: 720 mg/m ² /infusion	level 4: 1200 mg/m ² /infusion
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3 ^[2]
Units: number of DLT observed	0	0	0	0

Notes:

[2] - 2 patients inevaluable for DLT due to toxicity

End point values	level 5: 1800 mg/m ² /infusion			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: number of DLT observed	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Tumor objective response

End point title	Tumor objective response
-----------------	--------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Over treatment duration

End point values	level 1: 240 mg/m ² /infusio n	level 2: 480 mg/m ² /infusio n	level 3: 720 mg/m ² /infusio n	level 4: 1200 mg/m ² /infusio n
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	4 ^[3]
Units: number of patient with objective respons	1	1	0	0

Notes:

[3] - Patient n°11 (level 4) did not complete the first cycle of CT and had no tumor assessment. This pati

End point values	level 5: 1800 mg/m ² /infusio n			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: number of patient with objective respons	4			

Statistical analyses

No statistical analyses for this end point

Secondary: Efficacy

End point title	Efficacy
-----------------	----------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Rate of overall survival and rate of progression free survival

End point values	level 1: 240 mg/m ² /infusion	level 2: 480 mg/m ² /infusion	level 3: 720 mg/m ² /infusion	level 4: 1200 mg/m ² /infusion
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: median in months				
number (confidence interval 95%)				
Overall survival	7.6 (4.1 to 7.6)	6.2 (4.0 to 6.2)	5.5 (5.4 to 5.5)	7.8 (5.7 to 7.8)
Progression free survival	2.9 (1.5 to 2.9)	3.2 (2.1 to 3.2)	2.1 (1.9 to 2.1)	4.4 (2.5 to 4.4)

End point values	level 5: 1800 mg/m ² /infusion			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: median in months				
number (confidence interval 95%)				
Overall survival	9.8 (7.3 to 11.4)			
Progression free survival	4.6 (4.3 to 6.6)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

During the first 6 weeks of study treatment

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	2
--------------------	---

Reporting groups

Reporting group title	Whole population
-----------------------	------------------

Reporting group description: -

Serious adverse events	Whole population		
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 32 (40.63%)		
number of deaths (all causes)	31		
number of deaths resulting from adverse events	3		
Investigations			
WEIGHT DECREASED			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
WOLFF-PARKINSON-WHITE SYNDROME			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
BRAIN OEDEMA			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CEREBELLAR ATAXIA			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

CONVULSION				
subjects affected / exposed	1 / 32 (3.13%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
HEADACHE				
subjects affected / exposed	3 / 32 (9.38%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
HYDROCEPHALUS				
subjects affected / exposed	3 / 32 (9.38%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
INTRACRANIAL PRESSURE INCREASED				
subjects affected / exposed	2 / 32 (6.25%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
NERVOUS SYSTEM DISORDER				
subjects affected / exposed	2 / 32 (6.25%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
NEURALGIA				
subjects affected / exposed	1 / 32 (3.13%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
NERVOUS SYSTEM DISORDER (DISEASE PROGRESSION)				
subjects affected / exposed	1 / 32 (3.13%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
General disorders and administration site conditions				
FATIGUE / ASTHENIA				

subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
VOMITING			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
BRONCHIAL OBSTRUCTION			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
DYSPNOEA			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HYPOXIA			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
DEVICE RELATED INFECTION			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Whole population		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 32 (100.00%)		
Vascular disorders			

HAEMATOMA subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
HYPERTENSION subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4		
General disorders and administration site conditions ASTHENIA subjects affected / exposed occurrences (all)	24 / 32 (75.00%) 54		
GAIT DISTURBANCE subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3		
MUCOSAL INFLAMMATION subjects affected / exposed occurrences (all)	6 / 32 (18.75%) 7		
PYREXIA subjects affected / exposed occurrences (all)	12 / 32 (37.50%) 20		
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	13 / 32 (40.63%) 16		
DYSPNOEA subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
EPISTAXIS subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 5		
RHINORRHOEA subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Psychiatric disorders ANXIETY subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		

INSOMNIA subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
SLEEP DISORDER subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Investigations BLOOD PHOSPHORUS DECREASED subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3		
WEIGHT DECREASED subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3		
WEIGHT INCREASED subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 5		
Cardiac disorders SINUS TACHYCARDIA subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Nervous system disorders ATAXIA subjects affected / exposed occurrences (all)	7 / 32 (21.88%) 15		
CEREBELLAR ATAXIA subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 7		
CEREBELLAR SYNDROME subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 4		
CONVULSION subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
DYSARTHRIA subjects affected / exposed occurrences (all)	6 / 32 (18.75%) 11		
FACIAL NERVE DISORDER			

subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	8		
GLOSSOPHARYNGEAL NERVE DISORDER			
subjects affected / exposed	5 / 32 (15.63%)		
occurrences (all)	7		
HEADACHE			
subjects affected / exposed	21 / 32 (65.63%)		
occurrences (all)	77		
HEMIPARESIS			
subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	13		
HEMIPLEGIA			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
HYDROCEPHALUS			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	5		
IIIRD NERVE DISORDER			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	6		
INTRACRANIAL PRESSURE INCREASED			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
LANGUAGE DISORDER			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
MONOPARESIS			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
MUSCLE SPASTICITY			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	6		
NERVOUS SYSTEM DISORDER			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 32 (12.50%)</p> <p>7</p>		
<p>NYSTAGMUS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 32 (9.38%)</p> <p>4</p>		
<p>PARAESTHESIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>3</p>		
<p>PYRAMIDAL TRACT SYNDROME</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>10 / 32 (31.25%)</p> <p>25</p>		
<p>VIITH NERVE PARALYSIS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 32 (12.50%)</p> <p>9</p>		
<p>Blood and lymphatic system disorders</p> <p>LEUKOPENIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>6</p>		
<p>LYMPHOPENIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>14</p>		
<p>NEUTROPENIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>3</p>		
<p>Ear and labyrinth disorders</p> <p>TINNITUS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 32 (9.38%)</p> <p>3</p>		
<p>VERTIGO</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>2</p>		
<p>Eye disorders</p> <p>DIPLOPIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 32 (9.38%)</p> <p>4</p>		
<p>EYELID PTOSIS</p>			

subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	14 / 32 (43.75%)		
occurrences (all)	21		
CHEILITIS			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
CONSTIPATION			
subjects affected / exposed	18 / 32 (56.25%)		
occurrences (all)	32		
DIARRHOEA			
subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	7		
DYSPHAGIA			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	4		
NAUSEA			
subjects affected / exposed	11 / 32 (34.38%)		
occurrences (all)	13		
SALIVARY HYPERSECRETION			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
VOMITING			
subjects affected / exposed	20 / 32 (62.50%)		
occurrences (all)	65		
Skin and subcutaneous tissue disorders			
ACNE			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	3		
ALOPECIA			
subjects affected / exposed	6 / 32 (18.75%)		
occurrences (all)	6		
ERYTHEMA			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PETECHIAL PURPURA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PRURITUS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>RASH MACULO-PAPULAR</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>2</p> <p>2 / 32 (6.25%)</p> <p>2</p> <p>3 / 32 (9.38%)</p> <p>5</p> <p>3 / 32 (9.38%)</p> <p>3</p>		
<p>Endocrine disorders</p> <p>CUSHING'S SYNDROME</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>2</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>ARTHRALGIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BACK PAIN</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>MYALGIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PAIN IN EXTREMITY</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>TORTICOLLIS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 32 (9.38%)</p> <p>3</p> <p>3 / 32 (9.38%)</p> <p>3</p> <p>2 / 32 (6.25%)</p> <p>2</p> <p>4 / 32 (12.50%)</p> <p>4</p> <p>2 / 32 (6.25%)</p> <p>3</p>		
<p>Infections and infestations</p> <p>CONJUNCTIVITIS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>DEVICE RELATED INFECTION</p>	<p>3 / 32 (9.38%)</p> <p>3</p>		

subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
GINGIVITIS			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
INFECTION			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	3		
INFLUENZA			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
ORAL FUNGAL INFECTION			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
RHINITIS			
subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	8		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	3 / 32 (9.38%)		
occurrences (all)	7		
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	7 / 32 (21.88%)		
occurrences (all)	12		
HYPOCALCAEMIA			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	7		
HYPOKALAEMIA			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
HYPONATRAEMIA			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 November 2010	Update of trial site list : addition of a new trial site (CHU de Nantes), and declaration of new investigators among existing trial sites
09 March 2011	1. Update of cilengitide's IB 2. Update of information consent (for parents of minor patients and adults patients) following new safety features described in cilengitide's IB 3. Change of CRA monitor
08 August 2011	Update of trial site list : declaration of new investigators and removal of participating investigators among existing trial sites
13 February 2012	Update of trial site list : addition of a new trial site (CHU de Toulouse),
30 October 2012	1. Addition of new evaluation criteria (RANO, Revised Assessment in Neuro-Oncology) - as part of the centralized review process - to better assess the anti-tumor efficacy of the experimental treatment 2. Addition of cardiological exams for patients currently undergoing treatment and for future patients, following an episode of hypertrophic cardiomyopathy observed in a trial subject
12 February 2013	Change of IP (CHU de Nantes)
08 March 2013	Temporary suspension of enrolments following Merck's announcement of the results of the CENTRIC trial (in which cilengitide is being evaluated and for which the primary objective of overall survival was not achieved). Inclusions were suspended until the IDMC committee decided whether the benefit/risk balance was still positive
09 September 2013	1. Change of Cilengitide manufacturing site 2. Addition of exploratory investigations (mutation studies, etc.)

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported